Patents Represented by Attorney, Agent or Law Firm A. L. Klawitter
  • Patent number: 5840501
    Abstract: A method for determining the complexed forms of immunologically determinable prostate specific antigen (cPSA) in a blood sample, e.g., by two-site immunometric assays, in which the blood sample is treated to render free PSA (fPSA)immunologically nondetectable. A particularly preferred immunometric assay method employs three anti-PSA antibodies: an antibody that binds to both cPSA and fPSA (anti-tPSA), a second anti-tPSA antibody which is characterized by the unique property that binding to fPSA is blocked by binding of fPSA-specific antibodies, and a third antibody which is a fPSA-specific antibody. Thus, binding of the fPSA-specific antibody to PSA in the sample allows only cPSA to be measured in the immunometric assay. Measurement of cPSA blood levels has been found to provide a method for aiding in the diagnosis and monitoring of prostate cancer that is highly sensitive and specific, and eliminates the need for a significant number of patients to undergo unnecessary prostate biopsy.
    Type: Grant
    Filed: July 31, 1997
    Date of Patent: November 24, 1998
    Assignee: Bayer Corporation
    Inventors: William Jeffrey Allard, Kwok K. Yeung, Zeqi Zhou
  • Patent number: 5061790
    Abstract: A method for conferring or increasing the antigenicity of a disulfide-crosslinked protein by treating the protein with an oxidizing agent, such as periodate, having an oxidation potential sufficient to cleave disulfide linkages. Excess oxidizing agent is then inactivated by addition of a reducing agent. The resulting protein exhibits an increase in its ability to be bound by select antibodies, particularly monoclonal antibodies directed to linear peptide epitopes in the protein.
    Type: Grant
    Filed: July 10, 1989
    Date of Patent: October 29, 1991
    Assignee: Molecular Diagnostics, Inc.
    Inventors: James J. Elting, Heinz Kolbl
  • Patent number: 4996332
    Abstract: Optical indicator chalcogen (selenide or sulfide) compounds responsive to oxidants, e.g., hydrogen peroxide, and methods for preparing and using such indicators. Upon oxidation the resulting intermediate undergoes spontaneous elimination of the chalcogen residue to yield a signal compound which provides an optical signal such as fluorescence. Preferred fluorogenic indicator compounds are 3-chalcogen-3,4-dihydrocoumarin derivatives and 3-chalcogen-3,4-dihydro-2-quinolone derivatives. Such indicator compounds provide highly fluorescent products upon oxidation by hydrogen peroxide and are useful in analytical systems which generate hydrogen peroxide in response to the analyte under determination.
    Type: Grant
    Filed: June 13, 1988
    Date of Patent: February 26, 1991
    Assignee: Miles Inc.
    Inventors: Robert T. Buckler, Robert P. Hatch
  • Patent number: D444157
    Type: Grant
    Filed: July 14, 1998
    Date of Patent: June 26, 2001
    Assignee: Bayer Corporation
    Inventor: Lev Vant